Literature DB >> 8391856

A dosing study of nonoxynol-9 and genital irritation.

R E Roddy1, M Cordero, C Cordero, J A Fortney.   

Abstract

The objective of the study was to assess the symptoms and signs of genital irritation produced by different frequencies of nonoxynol-9 (N-9) use. Thirty-five women were randomized to each of 5 groups and used a vaginal suppository for 2 weeks. Group 1: N-9 once every other day; Group 2: N-9 once a day; Group 3: N-9 twice a day; Group 4: N-9 4 times a day; and Group 5: placebo 4 times a day. Study women were examined at admission, one week and 2 weeks with a colposcope for erythema and epithelial disruption, and were interviewed about vaginal itching and burning. The rates of reported symptoms for N-9 users were not significantly different from that of placebo users. The rate of epithelial disruption for women using N-9 every other day was essentially the same as that of women using placebo. The rates of epithelial disruption for women using N-9 1/day and 2/day were 2.5 times greater than that of placebo users. The rate of epithelial disruption for women using N-9 4/day was five times greater than that of placebo users. Genital irritation was located primarily on the vagina or cervix, and vulvitis was not a significant problem. Women who infrequently use N-9 products may not experience an increase in genital irritation. Women who choose to use N-9 frequently may experience an increase in epithelial disruption.

Entities:  

Keywords:  Americas; Biology; Caribbean; Clinical Research; Clinical Trials; Contraception; Contraceptive Agents; Contraceptive Methods; Developing Countries; Diseases; Dominican Republic; Family Planning; Genital Effects, Female; Genitalia; Genitalia, Female; Latin America; Nonoxynol-9; North America; Physiology; Signs And Symptoms; Spermicidal Contraceptive Agents; Urogenital System; Vaginal Spermicides; Vaginal Suppository

Mesh:

Substances:

Year:  1993        PMID: 8391856     DOI: 10.1177/095646249300400308

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  42 in total

1.  The Development of Microbicides for Clinical Use to Prevent Sexually Transmitted Diseases.

Authors:  David M. Phillips; Robin A. Maguire
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.725

2.  Thermoreversible gel formulations containing sodium lauryl sulfate or n-Lauroylsarcosine as potential topical microbicides against sexually transmitted diseases.

Authors:  S Roy; P Gourde; J Piret; A Désormeaux; J Lamontagne; C Haineault; R F Omar; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.

Authors:  Phalguni Gupta; Deena Ratner; Ming Ding; Bruce Patterson; Lisa C Rohan; Todd A Reinhart; Velpandi Ayyavoo; Xioli Huang; Dorothy L Patton; Bharat Ramratnam; Alexander M Cole
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

4.  Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.

Authors:  Renato S Aguiar; Luciana J Costa; Helena S Pereira; Rodrigo M Brindeiro; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

5.  Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides.

Authors:  H Irene Su; Courtney A Schreiber; Courtney Fay; Sam Parry; Michal A Elovitz; Jian Zhang; Alka Shaunik; Kurt Barnhart
Journal:  Contraception       Date:  2011-03-29       Impact factor: 3.375

6.  Self-reported discomfort associated with use of different nonoxynol-9 spermicides.

Authors:  P J Feldblum
Journal:  Genitourin Med       Date:  1996-12

7.  Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid.

Authors:  Deborah J Anderson; D'Nyce L Williams; Susan A Ballagh; Kurt Barnhart; Mitchell D Creinin; Daniel R Newman; Frederick P Bowman; Joseph A Politch; Ann C Duerr; Denise J Jamieson
Journal:  Am J Reprod Immunol       Date:  2009-02       Impact factor: 3.886

Review 8.  Contraceptive methods and the transmission of HIV: implications for family planning.

Authors:  C C Daly; G E Helling-Giese; J K Mati; D J Hunter
Journal:  Genitourin Med       Date:  1994-04

9.  Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.

Authors:  Bradley J Catalone; Tina M Kish-Catalone; Lynn R Budgeon; Elizabeth B Neely; Maelee Ferguson; Fred C Krebs; Mary K Howett; Mohamed Labib; Robert Rando; Brian Wigdahl
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations.

Authors:  Bryna Harwood; Leslie A Meyn; Susan A Ballagh; Elizabeth G Raymond; David F Archer; Mitchell D Creinin
Journal:  Am J Obstet Gynecol       Date:  2008-01       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.